Viewing nowSitauni Tablet 50 mg (Sitagliptin Hydrochloride Hydrate)
Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Korea Union Pharmaceutical Co., Ltd.

MFDS item code 202100086 · Approved 2021.01.06 · Insurance code 665508320
Improvement of glycemic control in type 2 diabetes mellitus
This medication is an adjunct to diet and exercise for improving blood sugar control in patients with type 2 diabetes. It can be used alone if starting on diabetes medication and can be used in combination with metformin if blood sugar control is insufficient. Patients inadequately controlled on sulfonylureas, metformin, thiazolidinediones, or insulin monotherapy can also receive this medication in combination. The drug can improve treatment outcomes even when combined with two or more drugs that do not adequately control blood sugar.
Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, section 5. General Precautions). Patients with renal impairment Because dosage adjustment based on renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dosage adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). No dosage adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.
This medication may cause severe allergic reactions after administration; if symptoms such as rash or difficulty breathing occur, discontinue use immediately and consult a physician. Pancreatitis may occur when using this medication, so notify healthcare providers immediately if symptoms such as abdominal pain or vomiting arise. Patients with type 1 diabetes or those allergic to this medication should not take it. Patients with impaired renal function may require dosage adjustments, and regular kidney function tests are important. While taking this medication, hypoglycemic symptoms may occur, so blood sugar should be checked regularly, especially when taken with other hypoglycemic agents such as insulin or sulfonylureas. Possible side effects during treatment include headache, upper respiratory infections, nasopharyngitis, diarrhea, nausea, and others. Pregnant or breastfeeding women are advised not to take this medication, and safety in children and adolescents under 18 has not been established. Elderly patients may have reduced kidney function, so dosage adjustments and monitoring of kidney function are necessary. In case of overdose, go to a hospital immediately for appropriate treatment; this medication can be partially removed by hemodialysis. This medication has relatively few interactions with other drugs, but caution is required when taken with digoxin, and consultation with a doctor or pharmacist is recommended. Report and seek treatment immediately if any adverse symptoms such as joint pain or skin blisters occur while taking this medication.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent exposure to air and moisture, at room temperature between 1 and 30 degrees Celsius. This will help maintain the drug's effectiveness and prevent degradation.
Light yellow pink round, biconvex film-coated tablet
30 tablets/box [(10 tablets/PTP×3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Korea Union Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.